Abstract
Can regenerative therapies help with gut health? Early research suggests they may have an important future role, especially by supporting repair of the intestinal lining, controlling inflammation, and influencing the gut microbiome. One area receiving attention is peptide research, including BPC-157 (Body Protection Compound-157). Laboratory and animal studies suggest that BPC-157 may support the protective mucosal lining, blood flow, tissue repair, and inflammatory balance. However, human research remains limited, and BPC-157 is not an FDA-approved drug for treating leaky gut, inflammatory bowel disease, ulcers, or other medical conditions.
Research is also exploring intestinal stem cells, microbiome-based treatments, cellular therapies, and other regenerative methods. These discoveries help explain how the intestine repairs itself, but many advanced therapies remain experimental. At Injury Medical Clinic PA in El Paso, Texas, an integrative model can bring medical oversight, functional medicine, rehabilitation, nutrition, and chiropractic care together. The goal is not to rely on one treatment. It is to understand the whole patient and support safer, evidence-informed care.
Can Regenerative Therapies Really Help the Gut?
The short answer is possibly, but the type of therapy and quality of evidence matter.
The digestive tract has a remarkable ability to repair itself. The intestinal lining is constantly replacing old and damaged cells. Specialized intestinal stem cells help produce the new cells needed to maintain this protective surface.
Researchers are learning that this repair system is influenced by:
Intestinal stem cells
Blood flow
Immune activity
Nutrition
Gut bacteria
Inflammatory signaling
Sleep and stress
Medications
Age
Chronic diseases
Recent research has shown that changes in the gut microbiome can directly influence intestinal stem-cell function. In mouse studies, restoring a younger microbial environment improved intestinal stem-cell activity and tissue regeneration (Kilbourne, 2026).
This matters because regenerative gut health may involve more than simply replacing damaged tissue. It may mean improving the biological environment that allows the intestine to repair itself.
Williams et al. (2023) proposed that changing the gut microbiome through diet, lifestyle, probiotics, and other methods can even be viewed as a form of regenerative medicine because these strategies may support the body's own repair systems.
What Is the Intestinal Barrier?
The intestinal lining is only a thin layer of cells, but it performs several major jobs.
It helps:
Absorb nutrients
Keep harmful organisms out of deeper tissues
Control immune reactions
Maintain water and electrolyte balance
Communicate with the gut microbiome
Protect the bloodstream from unwanted substances
The cells of this lining are connected by structures commonly called tight junctions.
When normal barrier control is disturbed, intestinal permeability may increase. This is sometimes called "leaky gut."
The medical term for increased intestinal permeability is more accurate because "leaky gut" is often used online as a broad explanation for many unrelated symptoms.
Increased intestinal permeability can occur with certain inflammatory, infectious, metabolic, and gastrointestinal disorders. Do not assume it is the cause of fatigue, pain, bloating, or other symptoms without proper medical evaluation.
Targeting Leaky Gut With Gastric-Protective Peptides
What Is BPC-157?
BPC-157, short for Body Protection Compound-157, is a synthetic peptide containing 15 amino acids. Researchers developed it from studies of protective compounds associated with gastric tissue.
BPC-157 has attracted attention because experimental studies suggest possible effects involving:
Gastrointestinal mucosal protection
Formation and regulation of blood vessels
Nitric oxide signaling
Cellular migration
Inflammatory signaling
Tissue repair
Tendon and ligament healing
Wound healing
Research involving the gastrointestinal system is especially interesting because BPC-157 has demonstrated cytoprotective activity in animal models involving ulcers, intestinal inflammation, esophageal injury, and other forms of digestive tissue damage.
However, there is an important difference between promising biology and a proven medical treatment.
A 2025 systematic review identified 36 qualifying BPC-157 studies, but 35 were preclinical, and only one included human clinical data. The authors concluded that the peptide is promising but that meaningful human safety and effectiveness evidence remains limited (Vasireddi et al., 2025).
A newer review published in 2026 reached a similar conclusion. Human exposure documented in published studies remains very small, standard pharmaceutical formulations and dosing have not been established, and larger controlled clinical trials are still needed (Mateescu et al., 2026).
How Might BPC-157 Affect the Gut Lining?
Experimental research suggests several possible pathways.
1. Supporting epithelial repair
The epithelial cells form the intestinal wall's protective surface. Animal and laboratory research suggests BPC-157 may influence cellular pathways involved in migration and tissue repair.
This could theoretically help damaged areas rebuild their protective surface.
2. Supporting blood flow
Healing tissue needs oxygen and nutrients.
BPC-157 research has examined pathways involving vascular endothelial growth factor, or VEGF, and nitric oxide signaling. These systems influence circulation and blood-vessel activity.
Improved blood flow around damaged tissue could theoretically create a better environment for repair.
3. Modulating inflammation
Chronic intestinal inflammation can interfere with normal healing.
Preclinical BPC-157 studies report changes in several inflammatory pathways. This has created interest in whether the peptide might someday have applications in inflammatory digestive diseases.
But animal findings cannot be assumed to produce the same benefit in people.
4. Supporting barrier integrity
BPC-157 has also been studied for its possible ability to protect gastrointestinal mucosa and maintain tissue integrity.
This is why researchers and integrative clinicians have become interested in the peptide in conversations about intestinal hyperpermeability.
Commercial integrative-health sources also discuss BPC-157 for gut repair, but these claims should be interpreted alongside the much more limited human clinical evidence (Yoo Direct Health, 2026).
Integrative Peptide Therapy and Full-Body Inflammation
The intestinal barrier is connected to the immune system.
When the barrier is damaged during a recognized disease process, microbial products and inflammatory signals can interact more strongly with immune tissues. Gut dysbiosis has also been associated with several inflammatory and autoimmune conditions.
Williams et al. (2023) described connections among gut dysbiosis, intestinal permeability, inflammatory cytokines, immune activity, and musculoskeletal disease.
This creates an interesting idea for integrative peptide therapy: instead of focusing only on symptoms, clinicians study whether biological signaling pathways involved in inflammation and tissue repair can be safely influenced.
However, integrative care should never mean that experimental therapies are automatically appropriate.
A responsible approach includes:
Reviewing the diagnosis
Studying medications
Looking for infection or inflammatory disease
Evaluating nutrition
Checking metabolic health
Reviewing kidney and liver function when appropriate
Discussing risks and evidence
Monitoring outcomes
Referring to gastroenterology when needed
BPC-157: An Important FDA and Safety Update
Patients should understand the difference between research interest, compounding policy, and FDA drug approval.
BPC-157 is not currently an FDA-approved drug for treating gut disorders.
In April 2026, the FDA removed BPC-157 from its previous Category 2 compounding list after earlier nominations were withdrawn. The agency then brought BPC-157-related substances before its Pharmacy Compounding Advisory Committee on July 23, 2026, specifically for consideration involving ulcerative colitis.
That regulatory review does not mean BPC-157 received FDA approval as a medication.
FDA drug approval requires a separate process demonstrating acceptable manufacturing, safety, dosing, and effectiveness.
The FDA has also previously noted limited human safety information and concerns involving peptide impurities and immune reactions in compounded BPC-157 products.
Competitive athletes need another warning. The 2026 World Anti-Doping Agency prohibited list specifically includes BPC-157 among non-approved substances prohibited at all times.
Stem Cells, the Microbiome, and Future Gut Repair
BPC-157 is only one part of regenerative gut research.
Scientists are also investigating how to encourage the intestine's own stem cells to repair damaged tissue.
Research from the International Society for Stem Cell Research reported that intestinal stem cell performance changes with age and that the gut microbiome can directly influence those cells (Kilbourne, 2026).
Other research has examined microbial metabolites that activate intestinal stem cells after severe damage caused by cancer treatment and stem-cell transplantation. In preclinical models, a microbiome-produced substance called desaminotyrosine helped strengthen the intestinal barrier and supported tissue regeneration (Leibniz Institute for Immunotherapy, 2025).
Researchers are even studying advanced immune-cell approaches. A 2025 Nature Aging study reported that anti-uPAR CAR T cells improved intestinal regeneration and reduced inflammation in older mice. Early laboratory findings were also seen in human intestinal cells. This is exciting science, but it is not a routine gut-health treatment (Cold Spring Harbor Laboratory, 2026).
Stem-cell approaches for inflammatory bowel disease have likewise been areas of research supported by organizations such as the California Institute for Regenerative Medicine.
These findings show where regenerative gastroenterology may be heading—not what every patient should receive today.
How Integrative Chiropractic Care Fits In
Chiropractic adjustments do not directly seal intestinal tight junctions or regenerate the intestinal lining.
Instead, chiropractic care can play a supportive role within a larger whole-person treatment plan.
For patients who also have back pain, neck pain, poor mobility, muscle tension, or physical deconditioning, chiropractic and rehabilitation may help improve:
Joint mobility
Movement mechanics
Physical activity tolerance
Posture
Musculoskeletal pain
Exercise participation
Functional recovery
Movement matters because regular physical activity can influence metabolic health, stress, circulation, sleep, and overall wellness.
Dr. Alexander Jimenez's published clinical approach emphasizes combining biological recovery with movement, rehabilitation, nutrition, functional medicine, and other appropriate services rather than expecting a single procedure to solve every problem (Jimenez, 2026a, 2026b).
A Multidisciplinary Approach in El Paso, Texas
At Injury Medical Clinic PA in El Paso, Texas, Dr. Alexander Jimenez, DC, APRN, FNP-BC, CCST, CFMP, IFMCP, ATN, works within a multidisciplinary model involving chiropractic care, functional medicine, rehabilitation, personal injury care, and medical collaboration.
Dr. Jimenez's practice information identifies Dr. Maria Guadalupe Cardenas, MD, as board-certified in internal medicine, with NPI #1164426749 and Texas MD license #J2933. She serves as medical director and collaborative physician.
Published clinic materials describe Dr. Cardenas as bringing more than 40 years of experience in internal medicine.
This type of medical-chiropractic collaboration can help place experimental or emerging treatments within a broader safety framework.
Dr. Cardenas can provide internal medicine oversight for medical problems, medications, laboratory findings, and systemic disease, while Dr. Jimenez addresses chiropractic, functional, biomechanical, rehabilitation, and related clinical factors within his professional scope.
The team can coordinate:
Internal medicine oversight
Chiropractic care
Functional medicine
Nutritional strategies
Personal injury care
Rehabilitation
Diagnostic evaluation
Lifestyle modification
Referral to gastrointestinal specialists when indicated
Evidence review before considering emerging therapies
That combination is particularly important when symptoms involve more than one body system.
When Gut Symptoms Need Medical Evaluation
Regenerative therapies should never delay diagnosis.
Medical evaluation is especially important with:
Blood in the stool
Black stools
Persistent vomiting
Severe abdominal pain
Unexplained weight loss
Fever
Severe diarrhea
Dehydration
Persistent constipation
Anemia
Difficulty swallowing
New symptoms after age 50
Conditions such as Crohn's disease, ulcerative colitis, celiac disease, infections, ulcers, gastrointestinal bleeding, and cancer require proper diagnostic testing and established medical care.
The Main Takeaway
Regenerative therapies may eventually become an important part of gut health treatment, but the science is still developing.
The most exciting discoveries show that intestinal healing involves much more than the intestinal wall itself. Stem cells, the microbiome, blood vessels, immune signaling, nutrition, metabolism, and inflammatory pathways communicate continuously.
BPC-157 is a particularly interesting experimental peptide because preclinical research suggests possible cytoprotective, mucosal, vascular, and tissue-repair effects. Yet human evidence remains too limited to claim that BPC-157 has been proven to repair leaky gut or treat gastrointestinal disease.
The safest path is therefore a multidisciplinary approach: identify the underlying condition, use established treatments when needed, improve nutrition and lifestyle factors, support healthy movement, and carefully evaluate emerging therapies as the evidence develops.
For Dr. Jimenez's clinical model in El Paso, this means combining integrative chiropractic care and rehabilitation with functional medicine strategies and the internal-medicine oversight of Dr. Maria Guadalupe Cardenas. The goal is not simply to chase symptoms. It is to understand how the patient's digestive, metabolic, inflammatory, and musculoskeletal systems may interact while keeping treatment grounded in safety and evolving scientific evidence.
References
California Institute for Regenerative Medicine. (n.d.). Stem cell therapy for inflammatory bowel disease.
Cold Spring Harbor Laboratory. (2026, January 3). Scientists found a way to help aging guts heal themselves. ScienceDaily.
Jimenez, A. (2026a). Regenerative medicine and integrative chiropractic approaches.
Jimenez, A. (2026b). Regenerative therapies for fitness and recovery insights.
Kilbourne, K. (2026, January 22). New study shows gut microbiota directly regulates intestinal stem cell aging. International Society for Stem Cell Research.
Leibniz Institute for Immunotherapy. (2025, October 28). Protecting the gut after stem cell transplantation: New evidence for the potential of microbiome-based therapies.
Mateescu, D.-M., Gavrilescu, D.-M., Constantinescu, F. E., et al. (2026). BPC-157 as an investigational peptide therapeutic: Biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics, 18(5), 625.
U.S. Food and Drug Administration. (2026). July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.
Vasireddi, N., Hahamyan, H., Salata, M. J., Karns, M., Calcei, J. G., Voos, J. E., & Apostolakos, J. M. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. HSS Journal, 21(4), 485–495. https://doi.org/10.1177/15563316251355551
Williams, K. L., Enslow, R., Suresh, S., Beaton, C., Hodge, M., & Brooks, A. E. (2023). Using the microbiome as a regenerative medicine strategy for autoimmune diseases. Biomedicines, 11(6), 1582. https://doi.org/10.3390/biomedicines11061582
World Anti-Doping Agency. (2026). 2026 prohibited list.
Yoo Direct Health. (2026, April 16). BPC-157: What the research says about healing and recovery.
The information herein is not intended to replace a one-on-one relationship with a qualified healthcare professional or licensed physician and is not medical advice. We encourage you to make healthcare decisions based on your research and partnership with a qualified healthcare professional. Our information scope is limited to chiropractic, musculoskeletal, and physical medicine, as well as wellness, sensitive health issues, and functional medicine articles, topics, and discussions. We provide and facilitate clinical collaboration with specialists across disciplines. Each specialist is governed by their professional scope of practice and the jurisdiction in which they are licensed. We utilize functional health and wellness protocols to treat and support care for musculoskeletal injuries or disorders. Our videos, posts, topics, subjects, and insights cover clinical matters and issues that directly or indirectly support our clinical scope of practice. Our office has made a reasonable effort to provide supportive citations and identify relevant research studies for our posts. We provide copies of supporting research studies upon request to regulatory boards and the public.
We are here to help you and your family.
Blessings
Dr. Alex Jimenez, DC, MSACP, APRN, FNP-BC*, CCST, IFMCP, CFMP, ATN
email: coach@elpasofunctionalmedicine.com
Multidisciplinary Licensing & Board Certifications:
Licensed as a Doctor of Chiropractic (DC) in Texas & New Mexico*
Texas DC License #: TX5807, Verified: TX5807
New Mexico DC License #: NM-DC2182, Verified: NM-DC2182
Multi-State Advanced Practice Registered Nurse (APRN*) in Texas & Multi-States
Multi-State Compact APRN License by Endorsement (42 States)
Texas APRN License #: 1191402, Verified: 1191402 *
Florida APRN License #: 11043890, Verified: APRN11043890 *
New York APRN License #: N25929, Verified: APRN-N25929*
License Verification Link: Nursys License Verifier
* Prescriptive Authority Authorized
ANCC FNP-BC: Board Certified Nurse Practitioner*
Compact Status: Multi-State License: Authorized to Practice in 40 States*
Graduate with Honors: ICHS: MSN-FNP (Family Nurse Practitioner Program)
Degree Granted. Master's in Family Practice MSN Diploma (Cum Laude)
Dr. Alex Jimenez, DC, APRN, FNP-BC*, CFMP, IFMCP, ATN, CCST
My Digital Business Card
Dr. Maria Cardenas, MD
(Board Certified in Internal Medicine)
Medical Director & Collaborative Physician
NPI # 1164426749
MD License #: J2933
